Insider Selling: Sagent Pharmaceuticals Major Shareholder Sells 47,826 Shares of Stock (SGNT)
Sagent Pharmaceuticals (NASDAQ:SGNT) major shareholder Morgan Stanley Investment Mana sold 47,826 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $20.27, for a total value of $969,433.02. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
A number of analysts have recently weighed in on SGNT shares. Analysts at RBC Capital upgraded shares of Sagent Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research note to investors on Wednesday, September 11th. They now have a $25.00 price target on the stock, up previously from $22.00. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Sagent Pharmaceuticals from $18.00 to $21.00 in a research note to investors on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Sagent Pharmaceuticals has an average rating of “Buy” and a consensus price target of $22.96.
Shares of Sagent Pharmaceuticals (NASDAQ:SGNT) traded up 0.54% during mid-day trading on Monday, hitting $20.50. 34,901 shares of the company’s stock traded hands. Sagent Pharmaceuticals has a 52-week low of $13.39 and a 52-week high of $24.27. The stock has a 50-day moving average of $22.05 and a 200-day moving average of $19.91. The company has a market cap of $578.1 million and a price-to-earnings ratio of 29.55.
Sagent Pharmaceuticals (NASDAQ:SGNT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.46 EPS for the quarter. The company had revenue of $59.60 million for the quarter, compared to the consensus estimate of $59.27 million.
Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.